Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
about
Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrierTariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.On the rate and extent of drug delivery to the brain.Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use.P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model.Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrierPeripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig.The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.Effects of hepatic ischemia-reperfusion injury on the P-glycoprotein activity at the liver canalicular membrane and blood-brain barrier determined by in vivo administration of rhodamine 123 in rats.Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.
P2860
Q30651426-79CBECB1-63DD-40D2-A54D-312FA118DAC8Q36638627-5126B98F-FD72-4AAF-A308-E8650856C44FQ36947632-A3351468-F08D-4ADF-8668-4518011617E3Q36949089-33585268-6687-4C32-B716-9FDA8AAB6BDCQ36949854-4AB0D3CF-6CFB-4F28-B263-EB87B7E4EFBEQ37023904-CBB36C49-2BE7-4F7A-8083-84181CA8E8BBQ37264538-49E71144-FF7C-4FC8-AEBF-50431A00A043Q37355679-1EECA48F-C215-4855-A7A7-F995C1ED0D09Q42484273-673946D4-835A-4084-AD93-C4786AD6E478Q42626124-AAB7482E-BD26-41CB-842F-771E351B34FFQ43069428-BCF049BE-5317-4432-A7B9-10C3EC9A69F1Q46677758-FD59A928-D59F-49F0-9ECC-DD446C55FF9EQ48176609-9077ED7A-8B4D-4756-9F9C-06D3008D6A0D
P2860
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@en
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@nl
type
label
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@en
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@nl
prefLabel
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@en
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@nl
P2093
P2860
P1476
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
@en
P2093
Margareta Hammarlund-Udenaes
Selma Sahin
P2860
P304
P356
10.1007/S11095-006-9780-0
P577
2006-04-07T00:00:00Z